Crown Reserve Acquisition Corp. I

For investors monitoring redemption mechanics and deal progress: the trust value per share is ~$10.05, slightly above the $10.00 redemption floor due to earned dividends. The redemption deadline is November 10, 2026 (extendable to February 10, 2027). There is no target identified yet, increasing the risk of liquidation if no deal is done in time. The material weakness and going concern opinion highlight governance and liquidity risks. Sponsor conduct appears standard (paid formation costs, holds founder shares with typical lock-ups, no insider trading arrangements adopted). The filing provides the first baseline financials for tracking future performance.

This procedural update alters secondary market liquidity and optionality without changing your tracked redemption timeline, trust account disclosures, or business combination deadline. Investors holding combined units must act through their brokers before the December 9, 2025 split date to preserve full economic packaging, while those seeking isolated equity ownership or warrant leverage can now trade components independently. The filing discloses a warrant exercise price of $11.50 per share and reiterates that the rights entitle holders to one-fifth of one ordinary share strictly upon consummation of an initial business combination. Corporate management’s press release includes forward-looking statements regarding the pursuit of a target acquisition, which the company attributes to standard pre-combination uncertainty and references risk factors in its final IPO prospectus. Chief Executive Officer Prashant Patel executed the filing, and Chief Financial Officer Eric Sherb is designated as the corporate contact. The document contains no new figures or claims regarding sponsor compensation, partner agreements, customer pipelines, revenue projections, proprietary technology, litigation developments, or amendments to existing contractual defenses.

This filing establishes the baseline financial mechanics for the SPAC. Key elements for investors: (1) Trust: $10.00 per unit deposited, for a total of $172,500,000. (2) Deadline: November 10, 2026 (12 months from IPO closing), with no extension provisions mentioned. (3) Redemption rights: Standard SPAC redemption rights at trust value ($10.00 per share) upon any business combination. (4) Founder shares: 4,312,500 Class B shares purchased for $25,000 (approximately $0.006 per share). The initial lock-up is one year after the business combination or earlier if share price reaches $12.00 for 20 out of 30 trading days starting 150 days post-combination. (5) Sponsor conduct: The sponsor covered IPO expenses via a $243,748 promissory note that was repaid at closing. The sponsor also agreed to a monthly $10,000 support services fee. The sponsor is liable for protecting the trust from vendor claims. (6) No target has been identified, and no substantive discussions have occurred.

This filing provides the definitive trust account funding, redemption mechanics, and deadline for shareholders. Investors can now track the trust value per share ($10.00 initially plus any interest) and the redemption deadline. The lack of any identified target means no imminent deal risk, but the one-year deadline starts the clock.

This 8-K establishes the baseline trust value ($10.00 per share) and the 12-month deadline for the company to complete a business combination. It sets the terms for warrants, rights, and sponsor lock-ups. Investors tracking redemption mechanics now have the trust size and deadline. The filing is the first substantive report after the SPAC's formation and IPO.

This filing establishes the baseline trust value ($10.23 per share as of filing, based on $150M trust / 15M public shares) and the redemption timeline investors need to track. The deadline is 12 months from the November 6, 2025 closing (approximately November 6, 2026), with potential extensions. The sponsor's nominal cost creates a strong incentive to complete any deal, and the 15% redemption cap (if a shareholder vote is held) is a key governance feature. The document also shows the full management team and their significant involvement in other SPACs, some of which liquidated or faced redemptions.

This filing is material because after months of amendments (at least seven prior amendments, given the reference to Amendment No. 7) and a declaration of effectiveness on Sept. 26, 2025, the SPAC was not yet priced. By filing this POS462C on Oct. 20, 2025, the SPAC is effectively re-starting the pricing process. This is the strongest signal yet that the company is ready to price and close its $150 million IPO imminently. For investors tracking the redemption calendar, the trust date is 12 months from closing; this filing suggests that the deal will close very soon, setting the 12-month deadline approximately 12 months from late October 2025. The shelf of redemptions is now activated for the incoming public shareholders. No target has been announced (status remains DEAL_ANNOUNCED).

This filing is the registration statement for a blank-check company's IPO, providing investors their first detailed look at the sponsor, management team, compensation, risk factors, and proposed offering structure. Key for redemption-calendar tracking: the trust is $10.00/share (standard), deadline is 12 months post-IPO (standard), with extension provisions noted. The high number of amendments (7) and the late September 2025 effective date suggest potential issues or delays in SEC review. The management team (Patel, Sherb) and directors (Peterson, Fell, Wadhwani, Doshi) have significant experience with other SPACs, some of which (Oceantech, Kernel, Integrated Wellness) failed to complete combinations and liquidated, which is a negative signal on track record. Low sponsor cost ($0.006/share) creates misaligned incentives. Unusual structure: private placement units at $8.00 (vs. $10.00 public) with non-managing sponsor investors, creating potential conflicts.

The amendment materially changes the economic terms of the offering for public investors and the sponsor. The addition of warrants and Share Rights alters the unit's value proposition. The private placement pricing at $8.00 per unit (vs. $10.00 previously) and the restructuring of lock-up periods affect sponsor incentives and potential dilution. The introduction of non-managing sponsor investors with founder share interests creates potential conflicts of interest. The trust value per share is $10.00, but the user's data shows $10.23, possibly reflecting accrued interest. The December 2027 deadline allows ample time for deal search. The filing is critical for investors evaluating the IPO because it defines the rights, trust mechanics, redemption procedures, and sponsor conduct.

The Registrant's confirmation of an automatic initial extension of three months directly adjusts the trust maintenance window and redemption horizon relative to the stated 2027-02-10 deadline. By contractually accepting that the liquidating distribution waiver covers private placement shares, the sponsor assumes reduced recovery priority upon dissolution, which materially shifts the effective trust value equation for public shareholders holding the $10.23-per-share deposits. Locking in that private placement units carry no adjustment provisions protects sponsor economics from public offering pricing volatility ahead of any business combination vote. Updating the subsequent events period through September 3, 2025 closes the financial reporting gap identified by the SEC. Because the filing specifies the exact allocation of the 17,681,250 total units across base offerings, over-allotments, and underwriter compensation—and breaks down their share/warrant/right components—investors now possess definitive mechanics for tracking dilution and warrant exercise rights. The document contains no references to target operations, customer contracts, revenue projections, technology, partnerships, or litigation; its substance is confined to SEC-mandated prospectus alignment, capital structure definitions, and corporate governance disclosures.

Unresolved SEC comments can delay effectiveness of the registration statement amendment, potentially constraining the timeline to consummate the announced business combination before the stated redemption deadline of 2027-02-10. Precise definitions of the automatic three-month extension, liquidating distribution waivers, and warrant accounting directly dictate how much capital remains in the trust per share if public shareholders exercise redemption rights versus remaining invested. Questions regarding voting thresholds and private placement unit adjustments indicate active structural revisions that may shift sponsor-to-public economic alignment ahead of any merger vote. The SEC’s rejection of specific Cayman Islands counsel assumptions signals a compliance risk that must be cured to maintain offering validity and proceed with the business combination. Resolution timelines and resulting term clarifications will determine whether current trust mechanics and sponsor commitments survive unchanged or require renegotiation prior to shareholder approval.

This filing sets the final terms for the SPAC's IPO, including the trust value ($10.00 per share), redemption rights, deadline for business combination (12 months, extendable up to 36 months), and sponsor compensation. It provides investors with the key mechanics for evaluating the investment, including dilution, conflicts of interest, and the structure of the securities.

These revisions materially redefine the arithmetic governing any future redemption event and shareholder approval vote. By anchoring the dilution framework to quartiles of the maximum redemption threshold tied to the $5,000,001 net tangible asset floor, investors now have a standardized method to model how much cash remains in the trust and what percentage of remaining shares absorbs the cost of un-redempted shares if the combination proceeds. Clarifying the voting math for the 15,000,000 public shares alongside the SAP block eliminates ambiguity about whether insider support alone can bypass a hostile redemption wave or if broader shareholder alignment is required. The upward revision of offering expenses to $745,000 reduces the net capital available for the target acquisition relative to prior expectations, while the SAP unit inclusion in the underwriting table signals specific sponsor-related equity commitments. Director background updates and ticker corrections mitigate compliance risk and provide transparency on sponsor continuity. Although the filing leaves the existing corporate timeline and trust balance untouched, the recalibrated redemption caps, dilution schedules, and approval thresholds directly alter the decision matrix for public shareholders evaluating whether to hold, tender, or wait for a further amendment.

This filing establishes the baseline SPAC mechanics that will apply once the IPO closes: public redemption rights at trust value, rights expiring worthless if no deal closes, a 24-month deadline starting from IPO closing with a stated expectation not to extend beyond 36 months, and a proposed trust deposit of $10.00 per unit. It also discloses sponsor economics and dilution — the sponsor paid $25,000 for 4,312,500 founder shares, or approximately $0.006 per share — plus underwriter compensation including 375,000 SAP units and a $300,000 deferred commission. It names management and directors, describes a healthcare/pharma/medtech/healthcare-IT acquisition focus, discloses prior SPAC histories of directors, states there is no material pending litigation, and includes an auditor going-concern explanatory paragraph. The status metadata figures of a $10.23 trust/share value and a 2027-02-10 deadline do not appear in this document; this document does not identify a target or start the combination clock.

The SEC staff’s comments dictate the pace and clarity of the upcoming initial business combination vote. By demanding reconciliation of the 5.6% and 16.3% voting requirement statements and confirmation of SAP share treatment, the staff is ensuring that redemption mechanics and post-combination ownership math are transparent before the registration becomes effective. The order to reformat dilution tables around quartiles of the maximum redemption threshold guarantees that investors evaluating the $10.23 per share trust can accurately model how extreme redemptions would affect net tangible assets and remaining equity. Scrutiny over the $500,000 versus $580,000 offering expense divergence and the inclusion of SAP units in underwriter compensation indicates continued examination of sponsor-side financial structures and fee allocations. Personnel reviews—including requests for Eric Sherb’s full five-year employment history and verification of Avinash Wadhwani’s directorship at Semper Paratus Acquisition Corporation (now doing business as Tevogen Bio)—highlight the staff’s focus on leadership accuracy and potential conflict disclosures. Until the amended registration is approved, effectiveness is deferred, but the corporate timeline and trust balance remain unchanged per this correspondence.

The document moves the SPAC closer to its IPO and sets the mechanics investors will rely on: a $10.00 trust per unit, a 24-month deadline extendable to 36 months, a fixed redemption process tied to a net tangible asset floor of $5,000,001, and significant sponsor/insider ownership terms. The inclusion of non-managing sponsor investors who may indirectly hold founder shares and private placement units introduces potential conflicts of interest regarding future business combination votes and redemption decisions.

This filing materially recalibrates the economic and procedural boundaries governing the SPAC’s capital structure and sponsor accountability. By anchoring redemption eligibility to a $5,000,001 net tangible asset threshold and shifting dilution modeling to quartile percentages of the maximum redemption, the Registrant establishes a transparent payout ceiling that directly informs shareholder exit timing and trust value preservation. The explicit commitment to cap extension activity at 36 months—despite acknowledging no formal statutory limit—provides a practical horizon aligned with Nasdaq maintenance rules, sharpening investor timelines around the February 2027 deadline. Disclosure of the sponsor’s unconstrained ability to abandon the vehicle pre-combination introduces governance risk that could delay transactions or force liquidation without automatically triggering redemption protections. The excise tax warning signals that aggressive public redemptions could financially penalize holdout investors, potentially altering redemption calculus and stabilizing the trust pool. Reconciled trust accounting eliminates valuation ambiguity, while precise dilution quantification and classified board structure enhance fiduciary oversight transparency. Although the submission constitutes routine regulatory compliance rather than a transaction announcement, the mechanical and risk disclosures materially reshape the framework for capital allocation, extension tolerance, and sponsor alignment ahead of any targeted business combination.

This filing is the definitive public disclosure of CRAC's IPO mechanics and sponsor conduct. The trust per-share value is $10.00, not $10.23 as indicated in the user's header. The deadline is 24 months from closing, with a maximum of 36 months. The sponsor paid $0.006 per founder share, creating a potential conflict of interest. The management team has prior involvement in several SPACs, including Oceantech Acquisitions I Corp. (which liquidated) and Kernel Group Holdings (which also liquidated). The filing also details the non-managing sponsor investors and their potential influence. These factors are material for investors assessing redemption timing, trust value, and alignment of sponsor incentives.

This document establishes the full terms of the SPAC's IPO structure, trust economics, redemption mechanics, sponsor economics, and the timeline for completing a business combination. It also provides audited financial data and details on the management team's background, including their prior SPAC experience (some of which resulted in liquidations). The trust value of $10.00 per share, the 15% redemption cap, the 24-month deadline (extendable to 36 months), and the significant dilution from the sponsor's nominal purchase price are all critical for investors.

This comment letter directly governs the contractual mechanics investors must evaluate before effectiveness. The SEC’s scrutiny of the $5,000,001 net tangible assets floor (#19) establishes the practical maximum redemption threshold, while trust funding inconsistencies (#7, #17) obscure actual cash availability. Extension limits (#6) leave the deadline mechanics unresolved until amended. Sponsor alignment requires resolution on fee structures (#10), dilution vectors from founder economics and working capital conversions (#11, #18), private purchasing compliance (#12), and sponsor continuity/foreign exposure (#14, #22, #28). The compulsory IR Act excise tax disclosure (#13) introduces a statutory mechanism that can shrink redemption proceeds or penalize non-redeeming holders, fundamentally altering the exit calculus. Until these 29 points are addressed and the registration statement accelerates, the precise terms governing cash payouts, extension flexibility, sponsor behavior, and dilution exposure remain unsettled, making this letter essential for accurate position sizing and deadline monitoring.

This is the initial public filing for a new SPAC, providing all key terms for investors evaluating the IPO. The trust value is $9.99 per share, the deadline is 24 months from closing, and the sponsor purchased founder shares at $0.006 per share, creating potential incentive conflicts. The filing details the underwriting compensation, including 375,000 SAP units, and the ability to extend the deadline via shareholder vote. No deal progress is reported, as this is a pre-IPO SPAC.

What changed: Quarterly report (Form 10-Q) for the period ended March 31, 2026. Trust value rose to $174,928,579 ($10.00 per share); net loss $263,493; warrant liability at $3,023,463; Business Combination Agreement with Carvix signed March 30, 2026, extending the Combination Period to February 10, 2027; Outside Date for closing is September 30, 2026; sponsor's due from related party decreased to $210,670; working capital deficit persists; material weakness in internal controls not fully remediated. Why it matters: Updates trust redemption mechanics, deadline extension, and deal progress—critical for redemption decisions. Carvix earnout targets disclosed. The filing confirms the SPAC is on track to complete the business combination but carries going concern risk if the deal fails.

What changed: A Joint Filing Agreement (Exhibit A) accompanying a Schedule 13G beneficial ownership report for the Class A Ordinary Shares of Crown Reserve Acquisition Corp. I. The filing creates a consolidated reporting arrangement for Westchester Capital Management, LLC and Westchester Capital Partners, LLC under Rule 13d-1(k). It contains no modifications to acquisition timelines, redemption windows, trust account distributions, extension vote triggers, or sponsor conduct disclosures. Why it matters: Investors tracking redemption deadlines, trust mechanics, deal progress, or sponsorship activity will find no new operational parameters, as this is a procedural regulatory exhibit. The document makes zero claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or executive compensation. The only attributed information originates from CaSaundra Wu, Chief Compliance Officer for both Westchester entities, who executed the agreement on May 15, 2026. Shareholder consolidation is documented strictly for SEC filing logistics; no positional percentages, acquisition targets, voting blocs, or capital structure adjustments are disclosed.

What changed: Form 425 filed as a current report on Form 8-K announcing the execution of a Business Combination Agreement between Crown Reserve Acquisition Corp. I (CRAC) and Carvix, Inc., including the full merger agreement and ancillary agreements. CRAC has entered into a definitive Business Combination Agreement with Carvix, Inc., valuing Carvix at $1 billion. Stockholders of Carvix will receive 50,000,001 shares of SPAC common stock at closing plus up to 50,000,100 earnout shares tied to EBITDA and revenue targets through 2030. Sponsor will receive up to 3,000,000 earnout shares. SPAC will seek at least $80 million in PIPE financing and a $20 million ELOC. Closing requires SPAC shareholder approval, SEC effectiveness of S-4, Nasdaq listing, and minimum $10 million cash after redemptions. Outside date is September 30, 2026. The post-closing board will have five members: four nominated by Carvix and one by the SPAC sponsor. Carvix management will continue to lead the combined company. Why it matters: This filing provides the full terms of the proposed business combination, including consideration, earnout targets, closing conditions, and governance structure. Shareholders can now evaluate the deal ahead of the shareholder vote and redemption deadline. The trust value per share is approximately $10.23 and redemptions will be permitted. The earnout structure and minimum cash condition are key for assessing post-deal value.

What changed: An SEC Form 8-K filed by Crown Reserve Acquisition Corp. I announcing entry into a Business Combination Agreement dated March 30, 2026 with Carvix, Inc. and CRAC Merger Sub Inc., together with related ancillary agreements and exhibits. CRAC has signed a definitive business combination agreement with Carvix. Under the terms, CRAC will domesticate to Delaware, Merger Sub will merge into Carvix, and Carvix stockholders will receive 50,000,001 shares of CRAC common stock at closing plus up to 50,000,100 Company Earnout Shares based on EBITDA and revenue targets, with up to 3,000,000 Sponsor Earnout Shares also available. The 8-K also reports that the trust fund holds no less than $174,894,694, that closing requires at least a $10,000,000 minimum cash amount and a $5,000,001 net tangible asset or penny-stock condition, and that the Outside Date is September 30, 2026. SPAC also disclosed an intended minimum PIPE of $80,000,000 and an ELOC commitment of $20,000,000, plus support agreements from Carvix stockholders holding a sufficient number of shares for the required company approval. Why it matters: This is the initial definitive filing establishing CRAC's deal terms and timeline. Investors tracking redemption mechanics should note the required redemption opportunity before closing, the minimum cash and net tangible asset conditions, the S-4/proxy and Nasdaq listing prerequisites, and the September 30, 2026 Outside Date. The filing also shows Carvix's existing management will lead the combined company and that the post-closing board will be five members, with four nominated by Carvix and one by the sponsor.

What changed: SEC Form 8-K furnishing a press release dated March 31, 2026 that announces a definitive Business Combination Agreement between Crown Reserve Acquisition Corp. I and Carvix, Inc. The press release, filed in this 8-K, formalizes a merger structure where a Crown Reserve subsidiary merges into Carvix, with Carvix surviving as a wholly owned operating subsidiary. Crown Reserve will domesticate from the Cayman Islands to Delaware and list the combined company on the Nasdaq Stock Market. The transaction values Carvix at an implied enterprise value of $1.0 billion, including earnout consideration, using an all-stock exchange based on a $10.00 per share reference value. Crown Reserve committed to reasonable best efforts to raise a minimum of $80.0 million in PIPE financing and a committed equity line of credit of no less than $20.0 million. Closing requires a minimum of $10.0 million in cash after redemptions, deferred underwriting fees, repayment of indebtedness, and transaction expenses. Earnout mechanics allow certain Carvix stockholders to receive up to 50,000,100 additional shares over four years beginning January 1, 2027, split equally into a revenue component (up to 25,000,050 shares) and an EBITDA component (up to 25,000,050 shares) with annual catch-up and true-up mechanics. The Sponsor qualifies for up to 3,000,000 additional shares (1,000,000 shares per year for the first three years) under identical milestones. Governance shifts to a five-member board (four Carvix nominees, one Sponsor nominee) with mutually agreed independent directors. Director/officer lock-ups run for eighteen months; the Sponsor faces a lock-up expiring the earlier of six months post-PIPE or eighteen months post-close. The agreement may be terminated if closing has not occurred by September 30, 2026, contingent on customary conditions including shareholder approval, S-4 effectiveness, Nasdaq listing, and the minimum cash condition. Why it matters: This filing materially accelerates the deal execution timeline and establishes clear mechanics for SPAC shareholders evaluating redemption decisions against the reported $10.23 trust per share baseline. The $10.00 per share reference value creates a structural valuation anchor that investors will compare to net trust assets when weighing redemption versus holding ahead of the required Form S-4 proxy statement/prospectus. The $10.0 million post-redemption cash requirement establishes a hard liquidity threshold that directly influences whether PIPE proceeds or credit lines must be drawn to consummate the merger. The September 30, 2026 termination window forces a decisive voting and closing schedule well before the SPAC's longer February 10, 2027 liquidation deadline, concentrating near-term catalyst risk. Sponsor alignment is structurally protected through the 3,000,000-share earnout tied to the same corporate milestones, mitigating typical pre-close incentive drift. On strategic substance, Ramin Farahmand, Co-Founder and Chief Executive Officer of Carvix, characterized the platform as a technology-led consolidator leveraging data-driven operational execution across a fragmented automotive services market. Eric Sherb, Managing Member of Crown Acquisition Sponsor LLC, cited demonstrated unit economics and a large, underserved market as reasons for selecting Carvix following an extensive search. The parties also intend the reorganization to qualify as tax-free under Internal Revenue Code Sections 368(a)(1)(F) and 368(a), with legal counsel identified as Whiteford, Taylor & Preston LLP and Zarif Law Group P.C. for Crown Reserve, Mitchell Silberberg & Knupp LLP for Carvix, and Thunder Rock Capital, LLC serving as financial advisor to Crown Reserve.

What changed: Form 10-K annual report for fiscal year ended December 31, 2025, the first such report since Crown Reserve Acquisition Corp. I's IPO on November 10, 2025. This is the initial 10-K filing since inception. Key changes: (1) IPO closed with 17,250,000 units at $10.00, raising $172.5 million; trust account held $173,403,838 at year-end, or approximately $10.05 per public share. (2) No business combination has been announced or is under substantive discussion; the company has 12 months (to Nov 10, 2026, automatically extended to Feb 10, 2027 upon signing a deal agreement) to complete a combination. (3) Management disclosed a material weakness in internal control over financial reporting related to accounting for complex financial instruments (warrant liabilities and public rights). (4) The independent auditor included a going concern explanatory paragraph. (5) Net income of $1,129,754 was reported, consisting entirely of trust investment income and a gain on warrant liability revaluation; no operating revenues. (6) The company held zero cash outside the trust and relies on the sponsor for working capital (receivable from sponsor of $448,082). (7) No executive compensation was paid. Why it matters: For investors monitoring redemption mechanics and deal progress: the trust value per share is ~$10.05, slightly above the $10.00 redemption floor due to earned dividends. The redemption deadline is November 10, 2026 (extendable to February 10, 2027). There is no target identified yet, increasing the risk of liquidation if no deal is done in time. The material weakness and going concern opinion highlight governance and liquidity risks. Sponsor conduct appears standard (paid formation costs, holds founder shares with typical lock-ups, no insider trading arrangements adopted). The filing provides the first baseline financials for tracking future performance.

What changed: A Schedule 13G beneficial ownership report accompanied by an attached EXHIBIT 99.1 Joint Filing Agreement. The filing establishes a unified regulatory reporting arrangement among MAGNETAR FINANCIAL LLC, MAGNETAR CAPITAL PARTNERS LP, SUPERNOVA MANAGEMENT LLC, and DAVID J. SNYDERMAN to submit a single Schedule 13G on behalf of all four parties regarding Crown Reserve Acquisition Corp. I shares as of December 31, 2025. Executed on February 17, 2026 by Hayley Stein as Attorney-in-fact for David J. Snyderman, the Joint Filing Agreement invokes Rule 13d-1(k) to permit consolidated disclosure. The exhibit discloses no share counts, acquisition costs, voting allocations, or pricing. Accordingly, it reports zero alterations to the SPAC's redemption mechanics, trust per-share accounting, business combination deadline, extension voting provisions, target due diligence status, or sponsor governance actions. Why it matters: This is a routine Securities Exchange Act compliance exhibit that clarifies how multiple Magnetar-affiliated vehicles and a named individual manager aggregate their positions for Section 13(d) transparency. For investors tracking the SPAC's path to a closing, the filing confirms coordinated holding behavior among the listed signatories but introduces no new commercial terms, conditional warrants, lock-up adjustments, or shareholder directives that would shift redemption economics or influence the announced deal trajectory. Because the text attributes no statements to management, the sponsor, or third-party analysts regarding customers, revenue projections, total addressable market, proprietary technology, strategic partnerships, active litigation, or executive succession plans, it carries no operational or valuation weight. Shareholders monitoring the pre-disclosed redemption window and trust balance should treat this document as a structural housekeeping update that confirms filing alignment rather than a catalyst for redemption timing or deal termination risk.

What changed: Routine compliance exhibit: Schedule 13G/A Joint Filing Agreement. The filing establishes a consolidated reporting arrangement under Rule 13d-1(k) among eight Harraden Circle affiliated entities and Frederick V. Fortmiller, Jr., permitting them to file amended Schedule 13G statements on a unified basis. It carries forward the SPAC’s existing operational framework: the $10.23 trust per share valuation, the 2027-02-10 business combination deadline, and the currently announced deal status remain entirely unmodified. No extension motions, redemption mechanic alterations, or sponsor conduct changes are documented. Why it matters: This agreement aggregates the Harraden Circle investment vehicles for SEC disclosure purposes, meaning future ownership updates will reflect collective block movements rather than fragmented entity filings. For investors tracking voting concentration and potential redemption pressure ahead of the stated deadline, it confirms that these related parties function as a single reporting group. The document contains no commercial substance: there are no customer claims, revenue figures, market size estimates, strategic pivots, technology validations, partnership announcements, litigation exposures, or executive interviews. Signed exclusively by Mr. Fortmiller as Managing Member across the relevant GPs and LPs, it serves purely as an administrative compliance instrument that leaves all transaction economics, target search progress, and investor protection mechanisms intact.

What changed: A Schedule 13G beneficial ownership report filed on February 11, 2026 (SEC file number 0000312069-26-000037) submitted by Barclays PLC to disclose its equity holdings in Crown Reserve Acquisition Corp. I. Barclays PLC reports its current beneficial ownership position in the issuer. The provided excerpt does not list exact share quantities, percentage thresholds, acquisition dates, or investment purpose declarations beyond the standard 13G classification. Accordingly, the filing contains no updates affecting the $10.23 trust value per share, the February 10, 2027 redemption deadline, extension mechanisms, merger execution status, or sponsor conduct. Why it matters: Beneficial ownership filings reveal institutional concentration and potential voting weight ahead of de-SPAC closures and shareholder approval windows. Barclays PLC’s submission confirms continued portfolio tracking of the security, but without the schedule’s underlying share counts, cost basis, or voting arrangements, the report cannot directly inform redemption expectations, capital commitment signals, or governance leverage relative to the stated deadline.